Ghandili, S.; Schönlein, M.; Wiessner, C.; Becher, H.; Lütgehetmann, M.; Brehm, T.T.; Schulze zur Wiesch, J.; Bokemeyer, C.; Sinn, M.; Weisel, K.C.;
et al. Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma. J. Clin. Med. 2021, 10, 5499.
https://doi.org/10.3390/jcm10235499
AMA Style
Ghandili S, Schönlein M, Wiessner C, Becher H, Lütgehetmann M, Brehm TT, Schulze zur Wiesch J, Bokemeyer C, Sinn M, Weisel KC,
et al. Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma. Journal of Clinical Medicine. 2021; 10(23):5499.
https://doi.org/10.3390/jcm10235499
Chicago/Turabian Style
Ghandili, Susanne, Martin Schönlein, Christian Wiessner, Heiko Becher, Marc Lütgehetmann, Thomas Theo Brehm, Julian Schulze zur Wiesch, Carsten Bokemeyer, Marianne Sinn, Katja C. Weisel,
and et al. 2021. "Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma" Journal of Clinical Medicine 10, no. 23: 5499.
https://doi.org/10.3390/jcm10235499
APA Style
Ghandili, S., Schönlein, M., Wiessner, C., Becher, H., Lütgehetmann, M., Brehm, T. T., Schulze zur Wiesch, J., Bokemeyer, C., Sinn, M., Weisel, K. C., & Leypoldt, L. B.
(2021). Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma. Journal of Clinical Medicine, 10(23), 5499.
https://doi.org/10.3390/jcm10235499
